NCT Number: NCT04789798
The direct and indirect costs of treating diabetes are high. 10-15% of the health budgets of many countries are spent on diabetes treatment. Most of these expenses are due to the treatment and follow-up costs of complications seen in patients who are not well monitored and whose metabolic control is not achieved. the rapid increase in diabetes causes polyclinic and hospital services to become more intense. Despite the increasing number of patients, both performance and due to non-physician occupational groups' insufficiency (Diabetes Dietician, Diabetes Nurse), patients can only be given an appointment once a year, and patients cannot be allocated sufficient time during the appointment. Since these problems are valid worldwide, Telemedicine programs are designed to provide easy, cheap, and practical follow-up and treatment of many chronic diseases in various states of the USA and many developed European countries.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Not applicable
The project is designed as a randomized controlled trial with approximately 100 subjects receiving a telemedicine intervention and approximately 100 receiving usual care. Eligibility requires having diabetes and being a Medicare beneficiary.
This program, called "TeleDiab" for the first time in our country, was designed in cooperation with the Istanbul University Rectorate and the local telecommunication company Turkcell. Its implementation was carried out as a pilot project in the Department of Endocrinology and Metabolic Diseases of Istanbul Medical Faculty in the follow-up and treatment of diabetic patients. Subjects are randomized to receive telemedicine case management or usual care for diabetes.
This project, it is aimed to evaluate the "TeleDiab" program developed for use in diabetic patients in terms of applicability, practicality, effectiveness, and cost-effectiveness. In this way, it was aimed to compare the electronically followed patient group with a similar patient group routinely followed in terms of glycemic control, treatment compliance, complications, and comorbid diseases 6 months and 1 year later.
The intervention utilizes a home telemedicine unit (HTU). The HTU is a specially designed, web-enabled device with a data port connected to a home glucometer and home blood pressure cuff whereby measurements obtained with these devices can be directly uploaded to a computer database. A diabetes nurse and a practitioner case manager interact regularly with intervention participants through videoconference via the HTU.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
for TeleDiab group:
for the control group:
Exclusion criteria
TeleDiab program components consist of:
Usual diabetes care, as provided by primary care providers
Time frame: Change in baseline capillary glucose levels (mg/dl) at 24th month
Time frame: Change in baseline home blood glucose measurement frequency at 24th month
Time frame: Change in baseline A1c (%) measurement frequency at 24th month
Time frame: Change in baseline weight (kg) measurement frequency at 24th month
Time frame: Change in baseline BMI (kg/m2) measurement frequency at 24th month
Time frame: Change from baseline to 24 months
retinopathy, peripheral neuropathy, autonomic neuropathy, nephropathy
Time frame: Change from baseline to 24 months
hyperlipidemia, hypertension, coronary artery disease, stroke, peripheral artery disease, general obesity, central obesity, clinical or subclinical hypo or hyperthyroidism, autoimmune trioiditis, celiac disease; gluten enteropathy, other
Time frame: Change from baseline to 24 months
Time frame: Change from baseline to 24 months
Time frame: Change from baseline to 24 months
Time frame: Change from baseline to 24 months
Time frame: Change from baseline to 24 months
Time frame: Change from baseline to 24 months
Time frame: Change from baseline to 24 months
Time frame: Change from baseline to 24 months
Time frame: Change from baseline to 24 months
Time frame: Change from baseline to 24 months
Time frame: Change from baseline to 24 months
Time frame: Change from baseline to 24 months
Istanbul University
Other
The Efficiency of Telemedicine to Optimize Metabolic Control in Patients With Diabetes in Turkey: Preliminary Results From The Randomised Controlled Telediab Trial
Acronym: TELEDIAB
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04010344
Cardiovascular Diseases, Diabetes
Kumasi, Ashanti Region, Ghana
View Trial DetailsNCT03520413
Diabetes Mellitus, Endocrine System Diseases
Durham, North Carolina, United States
View Trial DetailsNCT05311241
Teleconsultation, Telehealth
Paris, France
View Trial DetailsNCT03800316
Disease Attributes, Emergencies
Rochester, Minnesota, United States
View Trial Details